NCT06278350 - Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis | Biotech Hunter

Enrollment

161

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions

Plaque Psoriasis

Interventions

DRUG

D-2570

"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."

DRUG

Placebo

"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."

Trial Locations (1)

Peking University People's Hospital, Beijing